Bristol-Myers Squibb (BMY) Q4 2025 Earnings
Bristol-Myers Squibb reported Q4 2025 revenue of $12.5B (+1.3% YoY), beat analyst consensus of $12.3B by $221.7M. Diluted EPS came in at $1.26 (-24.6% YoY), beat the $1.23 consensus by $0.03. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Q4 2025 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q4 2025 earnings report.
Bristol-Myers Squibb (BMY) reported Q4 2025 earnings on February 5, 2026 before market open.
Bristol-Myers Squibb reported revenue of $12.5B and diluted EPS of $1.26 for Q4 2025.
Revenue beat the consensus estimate of $12.3B by $221.7M. EPS beat the consensus estimate of $1.23 by $0.03.
Compared to the same quarter a year prior, revenue grew 1.3% from $12.3B a year earlier and diluted EPS declined 24.6% from $1.67.
Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0000014272-26-000002) directly on SEC EDGAR. The filing index links above go to sec.gov.